Dr. Anthony M. Magliocco, MD FRCPC FCAP
President and CEO of Protean BioDiagnostics, Professor of Pathology and Oncology
Dr. Magliocco is a board-certified Pathologist and Professor of Oncology and Pathology with over 30 of years of experience in tissue pathology, medical research, molecular diagnostics, liquid biopsy, genetics, digital image analysis and clinical trials. He has founded and led multiple clinical laboratories and has overseen the deployment of numerous new laboratory tests in his career in both Canada and the USA. He has published over 200 research articles, has numerous patents issued and applied, and is a frequent invited speaker to international diagnostic technology meetings.
He was Chair of Pathology at the Moffitt Cancer Center, Scientific Director of the tissue core at Moffitt, and Chair of Pathology in the national cooperative groups RTOG and NRG oncology. In his extensive peer-reviewed research he has developed new digital image analysis methods and has created numerous new diagnostic tests used to aid selection of treatment plans for patients with breast, ovary, lung, bladder and many other cancers. He founded fellowship programs in digital imaging and molecular diagnostics at the Moffitt Cancer Center. He founded the hereditary cancer program in Saskatchewan and was the pathology leader of numerous tumor groups at the Tom Baker Cancer Center in Canada.
He also served as medical and scientific director of multiple regional and national tumor banks. His deep knowledge of molecular biology and medicine enable him to identify tests and tools that are unique in their ability to contribute to the future of medical diagnostics. His interest and aptitude for business enables him to create a viable pathway for implementation of these tests and tools. His vision is to move medical diagnostics forward to keep pace with scientific discoveries.
Most recently he has founded Protean BioDiagnostics. He has developed the unique Oncology MAPS system, which is currently the only comprehensive precision medicine system aimed at supporting community-based cancer patients and their doctors.
